News & Updates

Abdominal massage combined with standard laxative therapy significantly reduces constipation severity and faecal incontinence in children with functional constipation, according to a study presented at ESPGHAN 2026.

Treatment with lemborexant helps manage sleep disturbances in patients with liver cirrhosis, as shown in the crossover RESTORE trial.

Treatment with either low- or high-dose vedolizumab yields high rates of clinical remission in children with moderate-to-severe ulcerative colitis (UC), regardless of weight, according to the phase III KEPLER trial presented at ESPGHAN 2026.

Statin use may reduce the risk of cancer at several sites, including the liver, lung, colon, and rectum, especially for individuals with diabetes, as shown in a retrospective study.

Maintenance treatment with upadacitinib helps sustain remission in children with refractory ulcerative colitis (UC), according to a retrospective study.

Paediatric inflammatory bowel disease (IBD) patients who have achieved clinical remission on tumour necrosis factor inhibitor (anti-TNF) therapy are likely to flare if they stop treatment, researchers from the IBD Porto Group of ESPGHAN have found.

High coffee intake may have protective effects on the liver, with reduced risk of cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality, as reported in a study.

Elobixibat delivers superior symptom relief and quality-of-life improvements compared with prucalopride in the second-line treatment of patients with functional constipation, as shown in a head-to-head trial.